Immunocore Holdings (IMCR) EBITDA (2023 - 2026)

Immunocore Holdings has disclosed EBITDA across 4 years of filings, most recently posting $5.7 million for Q1 2026.

• EBITDA for Q1 2026 came in at $5.7 million, changed 0.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.8 million (down 54.23% YoY), and the FY2025 annual result was -$29.8 million, up 38.6% from the prior year.
• EBITDA came in at $5.7 million for Q1 2026 at Immunocore Holdings, up from -$28.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $12.0 million in Q3 2024 to a low of -$28.1 million in Q4 2025.
• The 4-year median for EBITDA is -$10.2 million (2023), against an average of -$8.4 million.
• Peak annual rise in EBITDA reached 185.32% in 2024, while the deepest fall reached 4508.57% in 2024.
• Immunocore Holdings' EBITDA stood at -$572000.0 in 2023, then sank by 4508.57% to -$26.4 million in 2024, then fell by 6.74% to -$28.1 million in 2025, then jumped by 120.19% to $5.7 million in 2026.
• The last three EBITDA figures came in at $5.7 million (Q1 2026), -$28.1 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.